With nearly 20 years of pharmaceutical and biotech experience,
'Under Tyler's leadership, Aktis has established an end-to-end supply chain model utilizing internal capabilities and facilities, complemented by external partners,' said
Since 2022,
Established multiple isotope supply agreements, spanning therapeutic and diagnostic uses, including further sources of Actinium-225 beyond the three supply agreements previously announced
Launched Aktis' state-of-the-art radiopharmaceutical development laboratory to apply proprietary insights into process development, formulation, and product development
Partnered with leading contract manufacturing organizations, including full logistical support, to ensure seamless and efficient patient supply of Aktis' proprietary targeted miniprotein radiopharmaceuticals
Commenced work on a GMP facility for clinical trial radiopharmaceutical manufacturing
Prior to joining Aktis,
'I am honored to accept this expanded leadership role,' said
About Aktis Oncology
Aktis Oncology is a clinical stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM BioImpact, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Part of a growing oncology pipeline, the company's lead program targets Nectin-4, a tumor-associated antigen found in urothelial and other cancers. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment. This approach would enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Aktis Oncology also has a strategic collaboration with
Contact:
Tel: (203) 682-8297
Email: Terri.Clevenger@westwicke.com
Tel: 443-213-0505
Email: Peter.Vozzo@westwicke.com
(C) 2024 Electronic News Publishing, source